GlassScriptPhysician profile
Xiaoyin Tang
NPI 1437128568
$4,973.84
in general payments reported to CMS, 2019-2025
41 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $301 · 2021: $279 · 2022: $606 · 2023: $626 · 2024: $701 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,941 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,940.62 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,096.03 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $468.87 | 2019-2025 | Evenity, Krystexxa, Enbrel |
| Glaxosmithkline, LLC. | $437.21 | 2019-2025 | Benlysta, Blujepa, Nucala |
| Janssen Biotech, INC. | $423.32 | 2022-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $252.29 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.84 | 2019-2025 | Cyltezo, Jardiance |
| Lilly USA, LLC | $225.43 | 2019-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $189.65 | 2022-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $173.84 | 2019-2025 | Orencia |
| Merck Sharp & Dohme LLC | $168.65 | 2019-2025 | Pifeltro, Delstrigo, Isentress |
| Pfizer INC. | $165.16 | 2019-2025 | |
| Horizon Therapeutics Plc | $97.99 | 2020-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $82.58 | 2023-2025 | Lupkynis |
| Organon LLC | $81.71 | 2023-2025 | Hadlima, Renflexis |
| Radius Health, INC. | $74.84 | 2020-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoyin Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.